| WB | 1/200-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/15-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | p33(CDK2) |
| WB Predicted band size | 34 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human CDK2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CDK2抗体的3篇参考文献的简要总结：
---
1. **文献名称**：*Cyclin-dependent kinases: engines, clocks, and microprocessors*
**作者**：Morgan, D. O.
**摘要**：该综述系统总结了CDK家族(包括CDK2)在细胞周期调控中的核心作用，并讨论了针对CDK2的特异性抗体的应用，如通过免疫印迹检测其在肿瘤细胞中的表达水平及活性变化。
2. **文献名称**：*Selective killing of cancer cells by a small molecule targeting the stress response to ROS*
**作者**：Schwartz, G. K. 等
**摘要**：研究通过CDK2特异性抗体验证了CDK2在癌细胞氧化应激反应中的关键作用，并发现抑制CDK2可选择性诱导癌细胞凋亡，为靶向治疗提供了实验依据。
3. **文献名称**：*Antibody-based profiling of CDK2 expression in human cancers*
**作者**：Malumbres, M. 等
**摘要**：该研究利用高特异性CDK2抗体，通过免疫组化分析了多种癌症组织样本，发现CDK2高表达与乳腺癌和卵巢癌患者预后不良显著相关，提示其作为生物标志物的潜力。
---
以上文献涵盖了CDK2抗体的功能研究、治疗应用及临床相关性，可作为相关领域的基础参考。如需具体文章链接或发表年份，可进一步补充信息。
CDK2 (Cyclin-dependent kinase 2) is a serine/threonine kinase critical for regulating cell cycle progression, particularly during the G1-to-S phase transition. It partners with cyclins (e.g., Cyclin E or A) to phosphorylate target proteins, such as retinoblastoma (Rb) protein, enabling cell cycle advancement. Dysregulation of CDK2 activity is linked to uncontrolled cell proliferation in cancers and other diseases, making it a therapeutic target.
CDK2 antibodies are essential tools for studying its expression, activation, and interactions. These antibodies specifically recognize CDK2 in techniques like Western blotting, immunohistochemistry (IHC), and immunoprecipitation (IP). Researchers use them to assess CDK2 levels in cancer tissues, monitor phosphorylation status (e.g., at Thr160 for activation), or evaluate drug effects in preclinical studies.
In drug development, CDK2 antibodies help validate inhibitors targeting CDK2-cyclin complexes, which are explored for cancer therapy. Specificity is crucial, as CDK2 shares structural homology with other CDK family members (e.g., CDK1. CDK4/6). High-quality antibodies distinguish CDK2 from related kinases, reducing cross-reactivity artifacts.
Overall, CDK2 antibodies bridge basic research and clinical applications, aiding in understanding cell cycle mechanisms and advancing targeted therapies for CDK2-associated disorders.
×
